MINNEAPOLIS, Aug. 11 /PRNewswire-FirstCall/ -- ATS Medical, Inc. today announced that the Securities and Exchange Commission (SEC) has declared effective the Company’s amended Form S-4 Registration Statement concerning its proposed acquisition of 3F Therapeutics.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO )
The Proxy Statement/Prospectus contained in the registration statement will be mailed on or about August 17, 2006 to ATS Medical stockholders of record as of July 28, 2006. The Company will hold its Annual Meeting of Stockholders on September 25, 2006, during which stockholders will be entitled to vote on the approval of the acquisition.
The acquisition is subject to customary closing conditions, including requisite approvals by ATS Medical stockholders. ATS Medical expects to close the proposed acquisition soon after it conducts the Annual Meeting of Stockholders and receives requisite stockholder approval.
ATS Medical stockholders are invited to attend its Annual Meeting of Stockholders to be held at 4:00 p.m. Central Time on Monday, September 25, at the Thrivent Financial for Lutherans Building, 625 Fourth Avenue South, Minneapolis, Minnesota.
About ATS Medical
ATS Medical, Inc. manufactures and markets products and services focused on cardiac surgery. The Company, global in scope, has been headquartered in Minneapolis since its founding in 1991. More than 100,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. ATS Medical’s focus on serving the cardiac surgery community is further strengthened by product and service offerings including ATS Simulus(TM) annuloplasty products for heart valve repair, Surgi-Frost(R) and Frost-Byte(R) products for surgical cryoablation of cardiac arrhythmias, RTI Cardiovascular for allograft tissue services, QAS home monitoring services for anticoagulation therapy, and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com .
Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company’s activities and results, please refer to the Company’s filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2005, as amended.
Additional Information and Where to Find It
ATS Medical has filed with the Securities and Exchange Commission a definitive proxy statement/prospectus and other documents regarding the proposed acquisition described in this press release. This proxy statement/prospectus will be sent to all security holders of ATS Medical seeking their approval of the transaction. Investors are urged to read the proxy statement/prospectus, which contains important information, including detailed risk factors. The proxy statement/prospectus and other documents filed by ATS Medical with the Securities and Exchange Commission are available free of charge at the SEC’s website, http://www.sec.gov , or by directing a request when such a filing is made to ATS Medical, 395 Annapolis Lane, Suite 105, Minneapolis, Minnesota, 55447, Attention: Investor Relations.
ATS Medical, its directors, and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the proposed transactions. Information about the directors and executive officers of ATS Medical and their ownership of ATS Medical stock is set forth in ATS Medical’s most recent filing on Form 10-K. Investors may obtain additional information regarding the interests of such participants by reading the revised proxy/prospectus statement.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comATS Medical, Inc.
CONTACT: Michael Dale, President-CEO of ATS Medical, Inc.,+1-763-553-7736, or Investors, Jennifer Beugelmans, +1-646-277-8704, orDoug Sherk, +1-415-896-6820, or Steve DiMattia, +1-646-277-8706 (Media),all of EVC Group, Inc.
Web site: http://www.atsmedical.com/
